1 / 4

Trametinib

Boc Sciences offers 871700-17-3 Trametinib in bulk, please inquire us to get a quote for 871700-17-3 Trametinib.<br>https://www.bocsci.com/trametinib-cas-871700-17-3-item-84-307744.html<br>

bocsci2018
Download Presentation

Trametinib

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trametinib - CAS 871700-17-3 Catalog number: B0084- 307744 A MEK inhibitor that suppresses MEK1 and MEK2 with IC50 of 0.92 and 1.8 nM and no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. It has been approved by FDA, in combination with Tafilnar, for the treatment of metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation. Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Inhibitor Targets MEK SARS-CoV-2 Molecular Formula C26H23FIN5O4 Molecular Weight 615.39 Ordering Information Catalo g Numbe r Siz e Pric e Stoc k Quantity B0084- 307744 500 mg $199In stock 0 Bulk Inquiry Add to cart Chemical Information Category Inhibitor

  2. Molecular Formula C26H23FIN5O4 Molecular Weight 615.39 Specification Properties QC Data Reference Reading     Purity ≥98% Appearance Off-White Solid Synonyms GSK-1120212; GSK 1120212; GSK1120212; JTP74057; JTP 74057; JTP-74057; Mekinist Clinical Trial Information NCT Number Title Condition Or Disease Phase Start Date Sponsor Status NCT00687622Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma Solid Tumours Phase 1 July 28, 2008 GlaxoSmithKline Completed NCT00920140Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias Cancer Phase 2 May 2011GlaxoSmithKline Completed NCT00955773A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects Cancer Phase 1 August 17, 2009 GlaxoSmithKline Completed NCT01037127Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated Cancer Phase 2 November 2009 GlaxoSmithKline Completed

  3. With or Without a BRAF Inhibitor NCT01072175Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 Cancer Phase 2 March 26, 2010 Novartis Pharmaceuticals Completed Preparing Stock Solutions ConcentrationVolumeMass 1 mg 5 mg 10 mg 1 mM 1.6250 mL 8.1249 mL 16.2499 mL 5 mM 0.3250 mL 1.6250 mL 3.2500 mL 10 mM 0.1625 mL 0.8125 mL 1.6250 mL 50 mM - - - Publication citing BOC Sciences Products Bio Calculators Solution Dilution Calculator  Molecular Weight Calculator  Molarity Calculator Stock concentration: *  molar (M) Desired final volume: * liters (L)

  4. Desired concentration: * molar (M) L * Our calculator is based on the following equation: Concentration (start) x Volume (start) = Concentration (final) x Volume (final) It is commonly abbreviated as: C1V1 = C2V2 https://www.bocsci.com/trametinib-cas-871700-17-3-item-84-307744.html

More Related